Trial
NCT05711628
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Recurrent Classic Hodgkin Lymphoma
Intervention
Autologous Hematopoietic Stem Cell Transplantation
Why stopped
Other - Protocol moved to Withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-20